Method studied/reference | Country | Participant characteristics | Outcomes assessed | Preferred treatment characteristics | Associated analytical theme |
Insulin pen- NovoPen Echo10 | Canada, Finland, Israel and Sweden | Participants diagnosed with type 1 diabetes (n=315). Aged 2–18 years | Rating effects of memory function in paediatric insulin devices |
|
|
Effect of subcutaneous tocilizumab (TCZ) administration on patient satisfaction and disease control12 | Turkey | Paediatric patients diagnosed with juvenile idiopathic arthritis (JIA) (n=39) who were switched from TCZ-IV to TCZ-SC (n=9). Age range 8.6–13.5 years | Questionnaire evaluating improvement in school performance, happiness with the drug and general satisfaction |
|
|
Intravenous and intramuscular administration of asparaginase13 | USA | Paediatric medical professionals who treat patients with acute lymphoblastic leukaemia (ALL) (n=74) | Online survey accessing practices and attitudes of physicians |
|
|
Patient and parent preference of sedation vs no sedation for intra-articular corticosteroid injections (IACI)14 | Bolivia | Patients and their parents who had received IACI with and without sedation (n=45). Median age 10.6 years | Preference for anaesthesiologist-controlled deep sedation with sevoflurane vs no sedation and associated characteristics |
|
|
Insuflon device (ID) for the administration of 15 | The Netherlands | Children receiving chemotherapy or requiring stem cell mobilisation (n=29). Median age of 3 years | Patient preferences for benefits, side effects and form of administration for ID |
|
|
Intravenous IgG (IVIg) treatment vs home treatment with subcutaneous IgG (SCIg)16 | Sweden | Children aged >1–<18 years with documented PID requiring IgG replacement therapy (n=12). Median age 10.9 years | Questionnaires assessed quality of life and healthcare resource utilisation following treatment change |
|
|
Preference and usability of the NovoTwist insulin pen needle vs conventional screw thread needles19 | UK | Children and adolescents with type 1 diabetes being treated with insulin (n=30). Age range 6–17 years | Preference and perception of ease of learning, ease of attachment and detachment of needle, and ease of disposal |
|
|
Perspectives and knowledge around allergen-specific immunotherapy (ASI) of parents20 | Turkey | Parents whose children were diagnosed with asthma and/or allergic rhinitis with positive skin prick test (n=198) | Survey evaluating the demographical and sociocultural characteristics of parents, knowledge levels and perspectives of parents |
|
|
Experience of parents who have given their infant enoxaparin26 | Australia | Parents/caregivers of children <12 months (n=11) | Experiences and educational needs of parents/caregivers |
|
|
Prefilled pen vs prefilled syringe of methotrexate (MTX) subcutaneous injection27 | Poland | Children diagnosed with JIA with ongoing subcutaneous MTX therapy (n=23). Median age 11.7 years | Preference for the MTX prefilled pen vs prefilled syringe after 1 month of treatment and comparison of experiences |
|
|
BPG reformulation preferences towards a new penicillin treatment30 | New Zealand | Children (n=50) (age range 10–21 years) receiving regular BPG injections for ARF/RHD, their family members (n=40) and health professionals (n=43) | Explored factors included experiences, preferences and drug characteristics for a new penicillin prevention and barriers and enablers to treatment |
|
|
Acceptability of long-acting injectable antiretroviral treatment (LAI-ART)32 | USA | Experienced HIV care providers (n=7), persons living with HIV (PLWH) (n=31) and parents of children living with HIV (n=5) | Semistructured focus group discussions to examine acceptability of LAI-ART, initial perception and desired attributes was examined |
|
|
Effects of regular needle injections on children and their parents’ daily living33 | Norway | Children with rheumatic disease (RD) aged 6–17 years (n=16) and their parents (n=16) who recently started needle injection treatment | Individual interviews and focus groups evaluated the effects of regular needle injections on daily living |
|
|
Barriers to administering non-oral medicines to children with chronic conditions 34 | UK | Children and their parents with chronic conditions (n=90). Age range 0–17 years | Semistructured interviews examined 88 barriers to administering non-oral medication |
|
|
ARF, acute rheumatic fever; BPG, benzathine penicillin G; JIA, juvenile idiopathic arthritis; RHD, rheumatic heart disease.